Kelly Scaggs Campen
Examiner (ID: 2758, Phone: (571)272-6740 , Office: P/3691 )
Most Active Art Unit | 3691 |
Art Unit(s) | 3624, 2165, 2164, 3312, 3738, 3691 |
Total Applications | 1052 |
Issued Applications | 501 |
Pending Applications | 228 |
Abandoned Applications | 322 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 16885431
[patent_doc_number] => 20210171626
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-10
[patent_title] => Methods and Compositions for Treating Aging-Associated Impairments with Trefoil Factor Family Member 2 Modulators
[patent_app_type] => utility
[patent_app_number] => 17/104344
[patent_app_country] => US
[patent_app_date] => 2020-11-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17669
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17104344
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/104344 | Methods and Compositions for Treating Aging-Associated Impairments with Trefoil Factor Family Member 2 Modulators | Nov 24, 2020 | Abandoned |
Array
(
[id] => 16686695
[patent_doc_number] => 20210069170
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-11
[patent_title] => TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH
[patent_app_type] => utility
[patent_app_number] => 16/951012
[patent_app_country] => US
[patent_app_date] => 2020-11-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28949
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16951012
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/951012 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | Nov 17, 2020 | Pending |
Array
(
[id] => 18117569
[patent_doc_number] => 11548950
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-01-10
[patent_title] => Agent, uses and methods for treatment
[patent_app_type] => utility
[patent_app_number] => 17/097457
[patent_app_country] => US
[patent_app_date] => 2020-11-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 40
[patent_figures_cnt] => 42
[patent_no_of_words] => 30051
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 81
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17097457
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/097457 | Agent, uses and methods for treatment | Nov 12, 2020 | Issued |
Array
(
[id] => 16854919
[patent_doc_number] => 20210155664
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-27
[patent_title] => REGENERATING FUNCTIONAL NEURONS FOR TREATMENT OF NEUROLOGICAL DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/072946
[patent_app_country] => US
[patent_app_date] => 2020-10-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26510
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17072946
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/072946 | REGENERATING FUNCTIONAL NEURONS FOR TREATMENT OF NEUROLOGICAL DISORDERS | Oct 15, 2020 | Pending |
Array
(
[id] => 16825689
[patent_doc_number] => 20210140982
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-13
[patent_title] => IDENTIFICATION OF SPATIAL BIOMARKERS OF BRAIN DISORDERS AND METHODS OF USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 17/073242
[patent_app_country] => US
[patent_app_date] => 2020-10-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 58904
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17073242
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/073242 | IDENTIFICATION OF SPATIAL BIOMARKERS OF BRAIN DISORDERS AND METHODS OF USING THE SAME | Oct 15, 2020 | Pending |
Array
(
[id] => 16614972
[patent_doc_number] => 20210033625
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-04
[patent_title] => DEFECTIVE CALCIUM SIGNALING AS A TOOL IN AUTISM SPECTRUM DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/068403
[patent_app_country] => US
[patent_app_date] => 2020-10-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11656
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 62
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17068403
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/068403 | DEFECTIVE CALCIUM SIGNALING AS A TOOL IN AUTISM SPECTRUM DISORDERS | Oct 11, 2020 | Pending |
Array
(
[id] => 16728992
[patent_doc_number] => 20210096139
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-01
[patent_title] => TAU KINETIC MEASUREMENTS
[patent_app_type] => utility
[patent_app_number] => 17/033047
[patent_app_country] => US
[patent_app_date] => 2020-09-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15415
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 165
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17033047
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/033047 | TAU KINETIC MEASUREMENTS | Sep 24, 2020 | Pending |
Array
(
[id] => 16748872
[patent_doc_number] => 20210100881
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-08
[patent_title] => METHODS FOR DIAGNOSING AND TREATING ALZHEIMER'S DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/025241
[patent_app_country] => US
[patent_app_date] => 2020-09-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16929
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 76
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17025241
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/025241 | Methods for diagnosing and treating Alzheimer's disease | Sep 17, 2020 | Issued |
Array
(
[id] => 18172707
[patent_doc_number] => 11572404
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-02-07
[patent_title] => Humanized anti-Tau(pS422) antibodies and methods of use
[patent_app_type] => utility
[patent_app_number] => 17/023963
[patent_app_country] => US
[patent_app_date] => 2020-09-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 16
[patent_no_of_words] => 40173
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17023963
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/023963 | Humanized anti-Tau(pS422) antibodies and methods of use | Sep 16, 2020 | Issued |
Array
(
[id] => 16914030
[patent_doc_number] => 20210187122
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-24
[patent_title] => MESSENGER RNA THERAPY FOR THE TREATMENT OF FRIEDREICH'S ATAXIA
[patent_app_type] => utility
[patent_app_number] => 17/016860
[patent_app_country] => US
[patent_app_date] => 2020-09-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21704
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17016860
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/016860 | MESSENGER RNA THERAPY FOR THE TREATMENT OF FRIEDREICH'S ATAXIA | Sep 9, 2020 | Pending |
Array
(
[id] => 16711949
[patent_doc_number] => 20210079096
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-18
[patent_title] => B7-H4 ANTIBODIES AND METHODS AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/006670
[patent_app_country] => US
[patent_app_date] => 2020-08-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25031
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17006670
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/006670 | B7-H4 antibodies and methods and use thereof | Aug 27, 2020 | Issued |
Array
(
[id] => 16512968
[patent_doc_number] => 20200392226
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-17
[patent_title] => ENZYMATIC MODIFICATION OF ANTI-AQP4 AUTOANTIBODY FOR MODULATING NEUROMYELITIS OPTICA
[patent_app_type] => utility
[patent_app_number] => 17/003153
[patent_app_country] => US
[patent_app_date] => 2020-08-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13408
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17003153
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/003153 | ENZYMATIC MODIFICATION OF ANTI-AQP4 AUTOANTIBODY FOR MODULATING NEUROMYELITIS OPTICA | Aug 25, 2020 | Abandoned |
Array
(
[id] => 16482367
[patent_doc_number] => 20200375967
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-03
[patent_title] => COMPOSITIONS OF PSILOCYBIN AND ANALOGS
[patent_app_type] => utility
[patent_app_number] => 16/992631
[patent_app_country] => US
[patent_app_date] => 2020-08-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5452
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16992631
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/992631 | COMPOSITIONS OF PSILOCYBIN AND ANALOGS | Aug 12, 2020 | Pending |
Array
(
[id] => 16466794
[patent_doc_number] => 20200368331
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-26
[patent_title] => Novel Method of Treating Macular Degeneration Using Botulinum Toxin-Based Pharmaceuticals
[patent_app_type] => utility
[patent_app_number] => 16/987831
[patent_app_country] => US
[patent_app_date] => 2020-08-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38185
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 93
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16987831
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/987831 | Novel Method of Treating Macular Degeneration Using Botulinum Toxin-Based Pharmaceuticals | Aug 6, 2020 | Pending |
Array
(
[id] => 18369138
[patent_doc_number] => 11649292
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-05-16
[patent_title] => Compositions and methods for treating and preventing inflammation
[patent_app_type] => utility
[patent_app_number] => 16/983185
[patent_app_country] => US
[patent_app_date] => 2020-08-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 86
[patent_figures_cnt] => 149
[patent_no_of_words] => 29657
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 70
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16983185
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/983185 | Compositions and methods for treating and preventing inflammation | Aug 2, 2020 | Issued |
Array
(
[id] => 16435734
[patent_doc_number] => 20200353059
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-12
[patent_title] => TPP-1 Formulations and Methods for Treating CLN2 Disease
[patent_app_type] => utility
[patent_app_number] => 16/941454
[patent_app_country] => US
[patent_app_date] => 2020-07-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16316
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -58
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16941454
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/941454 | TPP-1 formulations and methods for treating CLN2 disease | Jul 27, 2020 | Issued |
Array
(
[id] => 16398770
[patent_doc_number] => 20200339628
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-29
[patent_title] => ADVANTAGEOUS SALTS OF MU-OPIATE RECEPTOR PEPTIDES
[patent_app_type] => utility
[patent_app_number] => 16/929994
[patent_app_country] => US
[patent_app_date] => 2020-07-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8280
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16929994
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/929994 | ADVANTAGEOUS SALTS OF MU-OPIATE RECEPTOR PEPTIDES | Jul 14, 2020 | Abandoned |
Array
(
[id] => 16576629
[patent_doc_number] => 20210011030
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-14
[patent_title] => BLOCKADE OF TIM-1 PATHWAYS and P-SELECTIN PATHWAYS IN TREATMENT OF NEUROINFLAMMATORY DEGENERATIVE DISEASE
[patent_app_type] => utility
[patent_app_number] => 16/917330
[patent_app_country] => US
[patent_app_date] => 2020-06-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14925
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16917330
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/917330 | BLOCKADE OF TIM-1 PATHWAYS and P-SELECTIN PATHWAYS IN TREATMENT OF NEUROINFLAMMATORY DEGENERATIVE DISEASE | Jun 29, 2020 | Abandoned |
Array
(
[id] => 16506206
[patent_doc_number] => 20200385462
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-10
[patent_title] => ANTIBODY FOR USE IN DETECTING EARLY-STAGE DAMAGE OF BLOOD BRAIN BARRIER DURING CEREBRAL ISCHEMIC STROKE AND APPLICATION THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/910058
[patent_app_country] => US
[patent_app_date] => 2020-06-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4031
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16910058
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/910058 | ANTIBODY FOR USE IN DETECTING EARLY-STAGE DAMAGE OF BLOOD BRAIN BARRIER DURING CEREBRAL ISCHEMIC STROKE AND APPLICATION THEREOF | Jun 22, 2020 | Abandoned |
Array
(
[id] => 16582871
[patent_doc_number] => 20210017273
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-21
[patent_title] => ANTIBODY FOR DETECTING EARLY DAMAGE OF BLOOD-BRAIN BARRIER IN ISCHEMIC STROKE AND APPLICATION THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/907296
[patent_app_country] => US
[patent_app_date] => 2020-06-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4090
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16907296
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/907296 | ANTIBODY FOR DETECTING EARLY DAMAGE OF BLOOD-BRAIN BARRIER IN ISCHEMIC STROKE AND APPLICATION THEREOF | Jun 20, 2020 | Abandoned |